Clene Inc (CLNN)

$4.49

+0.03

(+0.67%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $4.40
    $4.67
    $4.49
    downward going graph

    2.0%

    Downside

    Day's Volatility :5.81%

    Upside

    3.89%

    downward going graph
  • $4.23
    $15.80
    $4.49
    downward going graph

    5.79%

    Downside

    52 Weeks Volatility :73.23%

    Upside

    71.58%

    downward going graph

Returns

PeriodClene IncSector (Health Care)Index (Russel 2000)
3 Months
-34.39%
6.5%
0.0%
6 Months
-57.76%
7.1%
0.0%
1 Year
-70.62%
9.8%
0.0%
3 Years
-97.13%
14.2%
-20.2%

Highlights

Market Capitalization
29.5M
Book Value
$0.66
Earnings Per Share (EPS)
-8.2
Wall Street Target Price
98.8
Profit Margin
0.0%
Operating Margin TTM
-12646.58%
Return On Assets TTM
-57.44%
Return On Equity TTM
-3702.24%
Revenue TTM
620.0K
Revenue Per Share TTM
0.11
Quarterly Revenue Growth YOY
-31.8%
Gross Profit TTM
447.0K
EBITDA
-37.3M
Diluted Eps TTM
-8.2
Quarterly Earnings Growth YOY
0.61
EPS Estimate Current Year
-6.14
EPS Estimate Next Year
-5.27
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Clene Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2100.45%

Current $4.49
Target $98.80

Technicals Summary

Sell

Neutral

Buy

Clene Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Clene Inc
Clene Inc
-36.49%
-57.76%
-70.62%
-97.13%
-97.52%
Kraft Heinz Company, The
Kraft Heinz Company, The
3.0%
-10.53%
-8.44%
-15.76%
4.52%
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
10.49%
8.24%
-16.86%
-12.43%
-8.02%
Hormel Foods Corporation
Hormel Foods Corporation
5.36%
2.74%
-21.98%
-32.63%
-23.05%
General Mills, Inc.
General Mills, Inc.
2.59%
2.05%
-13.08%
10.97%
22.73%
Kellanova
Kellanova
-0.17%
4.64%
-15.19%
-9.44%
-2.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Clene Inc
Clene Inc
4.14
NA
NA
-6.14
-37.02
-0.57
NA
0.66
Kraft Heinz Company, The
Kraft Heinz Company, The
14.79
14.79
1.02
2.77
0.06
0.04
0.05
40.79
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
27.09
27.09
2.48
2.86
0.14
0.05
0.02
19.83
Hormel Foods Corporation
Hormel Foods Corporation
22.51
22.51
2.96
1.6
0.1
0.05
0.04
14.39
General Mills, Inc.
General Mills, Inc.
15.2
15.2
1.98
4.5
0.25
0.07
0.04
16.81
Kellanova
Kellanova
24.25
24.25
2.93
0.79
0.21
0.05
0.04
9.24
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Clene Inc
Clene Inc
Buy
$29.5M
-97.52%
4.14
0.0%
Kraft Heinz Company, The
Kraft Heinz Company, The
Buy
$41.1B
4.52%
14.79
10.62%
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
Hold
$19.9B
-8.02%
27.09
11.07%
Hormel Foods Corporation
Hormel Foods Corporation
Hold
$17.3B
-23.05%
22.51
6.37%
General Mills, Inc.
General Mills, Inc.
Hold
$36.7B
22.73%
15.2
12.57%
Kellanova
Kellanova
Hold
$19.6B
-2.47%
24.25
7.09%

Insights on Clene Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 170.0K → 73.0K (in $), with an average decrease of 57.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -2.41M → -11.08M (in $), with an average decrease of 164.8% per quarter

  • Vs KHC

    In the last 1 year, Clene Inc has experienced a drawdown of -70.6%, however Kraft Heinz Company, The resisted the overall trend and outperformed by 62.2%

  • Vs GIS

    In the last 3 years, Clene Inc has experienced a drawdown of -97.1%, however General Mills, Inc. resisted the overall trend and outperformed by 81.3%

Company Information

clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.

Organization
Clene Inc
Employees
82
CEO
Mr. Robert Etherington MBA
Industry
Consumer Defensive

Discover More

FAQs